256 related articles for article (PubMed ID: 22573857)
1. Entecavir treatment of chronic hepatitis D.
Kabaçam G; Onder FO; Yakut M; Seven G; Karatayli SC; Karatayli E; Savas B; Idilman R; Bozdayi AM; Yurdaydin C
Clin Infect Dis; 2012 Sep; 55(5):645-50. PubMed ID: 22573857
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus concentrations in serum determined by sensitive quantitative assays in patients with established chronic hepatitis delta virus infection.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Zukeran H
J Med Virol; 2001 Nov; 65(3):478-84. PubMed ID: 11596082
[TBL] [Abstract][Full Text] [Related]
4. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
5. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine for chronic delta hepatitis.
Lau DT; Doo E; Park Y; Kleiner DE; Schmid P; Kuhns MC; Hoofnagle JH
Hepatology; 1999 Aug; 30(2):546-9. PubMed ID: 10421666
[TBL] [Abstract][Full Text] [Related]
7. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
8. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation.
Mederacke I; Filmann N; Yurdaydin C; Bremer B; Puls F; Zacher BJ; Heidrich B; Tillmann HL; Rosenau J; Bock CT; Savas B; Helfritz F; Lehner F; Strassburg CP; Klempnauer J; Wursthorn K; Lehmann U; Manns MP; Herrmann E; Wedemeyer H
J Hepatol; 2012 Jan; 56(1):115-22. PubMed ID: 21762665
[TBL] [Abstract][Full Text] [Related]
9. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
11. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D.
Schaper M; Rodriguez-Frias F; Jardi R; Tabernero D; Homs M; Ruiz G; Quer J; Esteban R; Buti M
J Hepatol; 2010 May; 52(5):658-64. PubMed ID: 20346531
[TBL] [Abstract][Full Text] [Related]
12. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
13. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study.
Niro GA; Ciancio A; Tillman HL; Lagget M; Olivero A; Perri F; Fontana R; Little N; Campbell F; Smedile A; Manns MP; Andriulli A; Rizzetto M
Aliment Pharmacol Ther; 2005 Aug; 22(3):227-32. PubMed ID: 16091060
[TBL] [Abstract][Full Text] [Related]
14. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis.
Zachou K; Yurdaydin C; Drebber U; Dalekos GN; Erhardt A; Cakaloglu Y; Degertekin H; Gurel S; Zeuzem S; Bozkaya H; Schlaphoff V; Dienes HP; Bock TC; Manns MP; Wedemeyer H;
Liver Int; 2010 Mar; 30(3):430-7. PubMed ID: 19840253
[TBL] [Abstract][Full Text] [Related]
15. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
[TBL] [Abstract][Full Text] [Related]
16. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of disease activity in patients of chronic hepatitis B virus, with and without superinfection with hepatitis D virus; an experience at tertiary care centre.
Das K; Ali H; Mahmood T; Munir SM; Ahmed T; Farooq MU
J Ayub Med Coll Abbottabad; 2008; 20(2):39-42. PubMed ID: 19385455
[TBL] [Abstract][Full Text] [Related]
18. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype.
Madejón A; Romero M; Hernández Á; García-Sánchez A; Sánchez-Carrillo M; Olveira A; García-Samaniego J
World J Gastroenterol; 2016 Mar; 22(11):3165-74. PubMed ID: 27003993
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.
Erhardt A; Gerlich W; Starke C; Wend U; Donner A; Sagir A; Heintges T; Häussinger D
Liver Int; 2006 Sep; 26(7):805-10. PubMed ID: 16911462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
